204
Participants
Start Date
October 31, 2025
Primary Completion Date
September 30, 2028
Study Completion Date
June 30, 2029
Sustained-release Dexamphetamine
"During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period."
Placebo
"Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group."
Leiden University Medical Center
OTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OTHER
Radboud University Medical Center
OTHER
The Netherlands Cancer Institute
OTHER
Het Zwarte Gat
UNKNOWN
Columbia University
OTHER
Parnassia Addiction Research Centre
OTHER